4 stories this morning, for surgeons and the people who support them.
- J&J says DePuy Synthes separation remains on track for mid-2027 and it is leaning toward a spin-off; Q3 orthopaedics sales rose 3.2% to $2.34B while spine fell 0.9% — J&J Q3 2026 results, October 13, 2026 (SEC 8-K exhibit 99.1: https://www.sec.gov/Archives/edgar/data/0000200406/000020040626000189/a2026q3exhibit991.htm): MedTech sales $8,642M, up 2.5%. CFO Joe Wolk's prepared remarks: 'we remain on track for the planned separation of DePuy Synthes by mid-2027' and 'we are leaning towards a spin as being the best option'; more detail at the Enterprise Business Review on December 8. ORTHOWORLD (October 15, 2026, https://www.orthoworld.com/depuy-synthes-on-track-for-mid-2027-spin-off-from-jj/): Q3 orthopaedics $2,344.5M (+3.2%); knees $385.4M (+2.5%), hips $419.1M (+3.2%), spine $206.3M (-0.9%), trauma $746.0M (+6.1%); nine-month spine -2%; MedTech EVP Tim Schmid attributed slower growth largely to the war in Iran, 'no longer limited to a handful of markets.' BNN Bloomberg and MassDevice also report the mid-2027 spin target. Follow-up to the 2026-09-15 episode on reported Apollo sale talks (~$20B); J&J's remarks do not mention a sale. Source
- Kuros Biosciences raises 2026 guidance to 36-40% sales growth after nine-month sales of $141.8M (+40%) and starts MagnetOs production in Alpharetta, Georgia — Kuros release, Schlieren, Switzerland, October 15, 2026: nine-month medical device sales USD 141.8M vs 101.1M (+40%); adjusted EBITDA USD 20.6M, 14.5% margin vs 12.1%; cash USD 19.6M. New 2026 guidance 36-40% sales growth and adjusted EBITDA margin above 14.5%; the H1 release (August 13, 2026) had guided at least 35% growth and about 14% margin, and confirmed 2028 targets of USD 300-330M. Alpharetta, Georgia site began commercial MagnetOs production in October, alongside Bilthoven, Netherlands. Trial enrollment: PROOF 97%, PRECISE 55%, ASTRA 18%. 2025 nine-month base of USD 101.1M corroborated by Moneycab (October 16, 2025). MagnetOs is cleared for use throughout the spine including interbody with an approved device, not as an osteoinductive graft. Source
- Amber Implants begins the U.S. introduction of its VCFix Spinal System, a pedicle-based expandable implant with cement for vertebral compression fractures — ORTHOWORLD, October 14, 2026, citing Amber Implants' October 13, 2026 GlobeNewswire release: Amber began the U.S. introduction of VCFix after its first U.S. clinical use. VCFix combines a pedicle-based expandable implant with cement fixation in one percutaneous procedure, aiming to restore vertebral height and support the anterior and posterior columns; Amber calls it minimally invasive vertebral reconstruction. FDA 510(k) K250637, decision date May 30, 2025, product code NDN (vertebroplasty bone cement), per openFDA. Background: FDA Breakthrough designation 2021; 10-patient first-in-human study in Mechernich, Germany, enrolled by June 2024. Competitive context: Stryker's SpineJack (510(k) 2018; SAKOS RCT non-inferior to balloon kyphoplasty at 12 months) and balloon kyphoplasty. First-case site, surgeon and launch scale not disclosed in available sources. Source
- HSS registry study at NASS 2026: robotic-arm MIS-TLIF associated with 16% lower in-hospital opioid use than navigation-guided MIS-TLIF in 804 patients — HSS release, San Antonio, October 15, 2026, presented at the NASS Annual Meeting: prospectively maintained registry, 804 one- or two-level MIS-TLIF patients from 2017 to 2025, 601 robotic arm-assisted and 203 navigation-guided, adjusted for patient characteristics, surgeon and other factors. Robotic group: 16% lower total in-hospital opioid consumption, 21% lower in the first 24 hours, 57% lower likelihood of needing IV PCA; no significant difference in complications or length of stay. Robot platform not named; percentages only, no MME. Co-authors Sheeraz Qureshi and Kyle Morse. Also carried by Ortho Spine News the same day. Observational, framed as an association. Source
Contribute to the Brief
Faculty can send the show a note — a reaction to a paper, a correction, a read on a rule change — either written, which we shape for broadcast and read in the show's voice, or as a voice note under three minutes, which airs in your own voice. Send one from Studio.
Not on doc social yet? Contribute a lecture or join the network — doc social is a clinical education platform for clinicians, and this show is one part of it.
Narration is synthesized. Reporting and editorial judgement are ours, and every story above links to its source.